GPIA/NPA Merger Seeks Unified Generic Industry Voice, Without NAPM
This article was originally published in The Tan Sheet
Executive Summary
The Generic Pharmaceutical Industry Association and the National Pharmaceutical Alliance hope that by merging they will move closer to establishing a unified voice for the generic industry on the eve of legislative debates over user fees and Waxman/Hatch reform.
You may also be interested in...
GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform
Generic drug user fees should be considered only in the context of changes to Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA at a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.
GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform
Generic drug user fees should be considered only in the context of changes to Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA at a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.
GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform
Generic drug user fees should be considered only in the context of changes to Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA at a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: